Welcome to our dedicated page for Allarity SEC filings (Ticker: ALLR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Allarity Therapeutics, Inc. SEC filings document the company’s clinical-stage oncology business, capital structure, governance, and material-event disclosures. The filings identify Allarity’s Nasdaq-listed common stock and emerging growth company status, and include 8-K reports covering Regulation FD presentations, scientific and clinical updates for stenoparib and the DRP® companion diagnostic, intellectual-property developments, operating and financial results, and promissory-note financing.
Proxy materials describe annual meeting matters and stockholder voting procedures, while material definitive agreement filings and other current reports provide formal disclosure on financing arrangements, corporate progress, and regulatory or clinical communications tied to Allarity’s precision oncology programs.
Graff Jeremy R. reported acquisition or exercise transactions in this Form 4 filing.
Allarity Therapeutics, Inc. reported that officer Jeremy R. Graff received a grant of 133,333 shares of common stock in the form of restricted stock units on January 28, 2026. The award was granted at a stated price of $0.00 per share as equity compensation.
The RSUs were issued under Allarity Therapeutics, Inc.'s Amended and Restated 2021 Equity Incentive Plan and will vest in three equal installments on the first, second, and third anniversaries of the grant date, as long as Graff maintains a continued relationship with the company. Following this grant, he directly holds 381,644 shares of common stock.
Ervin Jeffrey S reported acquisition or exercise transactions in this Form 4 filing.
Allarity Therapeutics, Inc. reported that its CFO, Jeffrey S. Ervin, received a grant of 150,000 shares of Common Stock in the form of restricted stock units at a stated price of $0.00 per share. Following this award, he holds 150,000 shares directly.
The RSUs were granted on January 28, 2026 under Allarity Therapeutics, Inc.'s Amended and Restated 2021 Equity Incentive Plan. They will vest in equal one-third installments on the first, second, and third anniversaries of the grant date, if he continues his relationship with the company through each vesting date.
Allarity Therapeutics, Inc. reported that the U.S. Patent and Trademark Office has issued a Notice of Allowance for its patent application covering the DRP® companion diagnostic specific to its cancer drug candidate stenoparib. The patent is expected to be formally granted within three months, subject to standard administrative procedures, and would provide exclusivity at least into 2039 for stenoparib when used together with the DRP® test.
The allowed claims cover methods for predicting clinical benefit from stenoparib using gene expression profiles and selecting patients most likely to respond. Allarity already holds European and Australian patents for the Stenoparib DRP® and 18 granted patents for other drug-specific DRPs, including eight in the United States. The company continues Phase 2 development of stenoparib in ovarian cancer and small cell lung cancer while pursuing additional DRP® patent protection globally.
Allarity Therapeutics is registering the resale of up to 255,103 shares of its common stock. This prospectus covers resale of those shares by a selling stockholder (the shares were issued in a private placement on December 23, 2025). The Company will receive no proceeds from these resales.
The prospectus states the selling stockholder may sell the Shares from time to time on Nasdaq or in private transactions at prevailing market or negotiated prices. The prospectus also discloses prior related financings, including a September 23, 2025 private placement generating approximately $2.5 million in gross proceeds and an Additional Closing on December 23, 2025 that issued 255,103 shares at $0.98 per share.
Allarity Therapeutics, Inc. filed Amendment No. 1 to its registration statement (File No. 333-293420) on April 24, 2026 as an exhibits-only amendment to furnish an updated auditor consent. The Amendment updates Exhibit 23.1 and includes the facing page, Item 16, signature page, exhibit index, and filed exhibits; the prospectus is unchanged.
Allarity Therapeutics, Inc. filed a current report describing two new scientific posters on its lead drug candidate stenoparib and its DRP® companion diagnostic, presented at the AACR Annual Meeting 2026 in San Diego.
One poster links higher stenoparib DRP® scores with enhanced overall survival in a phase 2 trial in advanced, recurrent ovarian cancer, supporting DRP-based patient selection. The second poster shows stenoparib’s dual PARP/tankyrase mechanism can modulate the WNT/β-catenin signaling pathway and inhibit growth of colorectal cancer cell lines at clinically relevant concentrations.
The company emphasizes stenoparib’s potential in colorectal and ovarian cancers and highlights ongoing phase 2 trials in ovarian cancer and small cell lung cancer, alongside broader plans to use its DRP® platform to identify patients most likely to benefit from treatment.
Allarity Therapeutics, Inc. has filed a proxy statement for its 2026 Annual Meeting of Stockholders to be held virtually on June 26, 2026. The meeting (record date May 7, 2026) asks shareholders to vote on director election, ratification of Wolf & Company as auditors, an amendment to increase the 2021 Equity Incentive Plan reserve from 1,521,990 to 2,021,990 shares, a non-binding say-on-pay vote, Nasdaq 20% Rule approval related to an equity line providing up to $6,000,000, a certificate amendment to permit officer exculpation (requiring 66-2/3% of outstanding shares to approve), and an adjournment proposal. The proxy explains voting mechanics for virtual attendance, quorum rules (one-third quorum) and broker voting treatments for each proposal.
Allarity Therapeutics reported 2025 results showing its first revenue and a sharply reduced loss as it advanced cancer drug stenoparib. Revenue reached $320 thousand from licensing agreements, compared to no revenue in 2024.
Net loss attributable to shareholders narrowed to $11.2 million, or $0.78 per share, versus $25.1 million, or $15.65 per share, reflecting lower operating costs. General and administrative expenses fell to $6.3 million from $11.4 million, while R&D rose modestly to $6.6 million. Cash was $14.7 million and total liabilities declined to $8.4 million as of December 31, 2025.
Allarity Therapeutics, Inc. files its annual report describing a refocused business built around stenoparib, a dual PARP/tankyrase inhibitor for difficult-to-treat cancers. The company’s proprietary DRP® companion diagnostic platform is used to select patients most likely to respond, aiming for smaller, more effective trials.
Management has terminated other programs to conserve capital and concentrate on stenoparib and its DRP®. Stenoparib is in Phase 2 ovarian cancer studies and a separate VA-funded trial in relapsed small cell lung cancer, and received FDA fast-track designation for advanced recurrent ovarian cancer.
The report highlights extensive DRP® intellectual property, multiple partnerships, and a license with Eisai that includes development milestones, royalties and a potential buy-back option. Allarity is an emerging growth and smaller reporting company, disclosing substantial funding needs and continued reliance on Nasdaq listing compliance.